Dr Marianne Hansson received her PhD at the Royal Institute of Technology (KTH) Stockholm, Sweden in 1998. The same year Affibody Medical AB was founded, and Marianne was one of the first three employees in Affibody and held positions as project manager and as business development manager. In 2006 Marianne was recruited to start up Atlas Antibodies AB and she served as CEO until 2017, during which time the company grew to 50 employees and a yearly revenue of 90 million SEK.

Since October 2017, Marianne is CEO of ScandiBio Therapeutics AB and ScandiEdge Therapeutics AB.

She is a co-founder of Affibody Medical AB, Atlas Antibodies AB, ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB, Amylonix AB and A05 Diagnostics AB.

Marianne Hansson is a member of the board of directors of Q-linea AB (publ) and Intervacc AB (publ).